1151 / 1631
Highly criticized:
• Poor protocol adherence
• Non-inferiority goal in OS not met
• Insufficient toxicity evaluation
• Overall poor results, sub-optimal chemo
• Neurotoxicity even with chemo alone (26%), with RT (49%)
• Salvage improved survival, but carries high QOL/toxicity cost
Thiel et al, Lancet Oncol 2010